Montreal - ProMetic Life Sciences Inc. has released additional positive data resulting from further analysis following a Phase I clinical study with PBI-1402. The analysis, performed by two external firms, confirms that the drug, taken orally, not only increases the absolute and relative number of reticulocytes in blood but also the number of burst-forming unit-erythroid cells (BFU-E), the precursors of reticulocytes. This strengthens the expected use of PBI-1402 for the treatment of anemia.
"The safety profile demonstrated by PBI-1402 during this trial suggests that the drug will be well tolerated during chronic therapy," said Dr. Christopher Penney, Chief Scientific Officer and Vice- President of R&D, Therapeutics. "Obtaining early evidence of biological activity in a Phase I trial is a major bonus," added Dr. Penney.
"This new drug could play a major role in the treatment of anemia induced by chemotherapy and renal dialysis," said Dr. Denis Claude Roy, Hematologist and Director, Cellular Therapy Laboratory at Maisonneuve-Rosemont Hospital, and principal investigator of this study. "The follow-up trials will be designed to demonstrate clinical efficacy of PBI-1402 alone or in combination with erythropoietin."
No comments:
Post a Comment